Avelumab, for Metastatic Merkel Cell Carcinoma | Observed Responses are Durable

Avelumab, for Metastatic Merkel Cell Carcinoma | Observed Responses are Durable

Annual-Meeting

1 year
131 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Paul Nghiem, MD, PhD, University of Washington, explains Avelumab, for Metastatic Merkel Cell Carcinoma | Observed Responses are Durable at Annual Meeting 2018
Up Next Autoplay
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Category: Melanoma and Skin Cancer
13 Views
UVA Cancer Center 2 months
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
28 Views
UVA Cancer Center 2 months
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Category: Melanoma and Skin Cancer
40 Views
Cancer-News 2 months
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Category: Melanoma and Skin Cancer
35 Views
Cancer-News 3 months
Will the CheckMate 204 data affect clinicians?
Will the CheckMate 204 data affect clinicians?
Category: Melanoma and Skin Cancer
24 Views
moasc 5 months
CheckMate 204 Study
CheckMate 204 Study
Category: Melanoma and Skin Cancer
23 Views
moasc 5 months
Clinicians could change the way they manage their patients
Clinicians could change the way they manage their patients
Category: Melanoma and Skin Cancer
4 Views
moasc 5 months
Fixing toxic therapy
Fixing toxic therapy
Category: Melanoma and Skin Cancer
8 Views
moasc 5 months
Alternate dosing for immunotherapy
Alternate dosing for immunotherapy
Category: Melanoma and Skin Cancer
4 Views
moasc 5 months
Is this data practice changing for clinicians?
Is this data practice changing for clinicians?
Category: Melanoma and Skin Cancer
4 Views
moasc 5 months